Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome

Maria I Vazquez Roque, Ernest P. Bouras

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.

Original languageEnglish (US)
Pages (from-to)203-211
Number of pages9
JournalAdvances in Therapy
Volume30
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Irritable Bowel Syndrome
Constipation
Therapeutics
Drug Approval
Biological Availability
Prescriptions
linaclotide
Clinical Trials
Safety
Health

Keywords

  • Constipation
  • Gastroenterology
  • Guanylate cyclase C
  • Guanylin
  • Irritable bowel syndrome
  • Linaclotide
  • Uroguanylin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

@article{1fdb649074654df9af38fd1fad46486b,
title = "Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome",
abstract = "Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.",
keywords = "Constipation, Gastroenterology, Guanylate cyclase C, Guanylin, Irritable bowel syndrome, Linaclotide, Uroguanylin",
author = "{Vazquez Roque}, {Maria I} and Bouras, {Ernest P.}",
year = "2013",
doi = "10.1007/s12325-013-0012-9",
language = "English (US)",
volume = "30",
pages = "203--211",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "3",

}

TY - JOUR

T1 - Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome

AU - Vazquez Roque, Maria I

AU - Bouras, Ernest P.

PY - 2013

Y1 - 2013

N2 - Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.

AB - Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.

KW - Constipation

KW - Gastroenterology

KW - Guanylate cyclase C

KW - Guanylin

KW - Irritable bowel syndrome

KW - Linaclotide

KW - Uroguanylin

UR - http://www.scopus.com/inward/record.url?scp=84891618920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891618920&partnerID=8YFLogxK

U2 - 10.1007/s12325-013-0012-9

DO - 10.1007/s12325-013-0012-9

M3 - Article

C2 - 23436110

AN - SCOPUS:84891618920

VL - 30

SP - 203

EP - 211

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 3

ER -